Equities

PureTech Health PLC

PureTech Health PLC

Actions
Health CarePharmaceuticals & Biotechnology
  • Price (GBX)291.00
  • Today's Change-12.00 / -3.96%
  • Shares traded92.85k
  • 1 Year change71.18%
  • Beta0.9064
Data delayed at least 20 minutes, as of Jan 27 2020 16:35 GMT.
More ▼

Profile data is unavailable for this security.

About the company

PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets. This segment includes subsidiary companies, which include Vedanta Biosciences, Inc., Gelesis, Inc., Akili Interactive Lab, Inc., Tal Medical, Inc., Karuna Pharmaceuticals, Inc., Entrega Inc. and Follica Incorporated. Businesses in the project phase businesses segment are those whose activities are focused on financing, sourcing and creating new product candidates and newly created businesses whose technologies are in the process of validation. This segment includes subsidiary companies, which include The Sync Project Inc., Sonde Health, Inc., Commense Inc., Alivio Therapeutics, Inc., Vor Biopharma Inc., Enlight Biosciences, LLC, Mandara Sciences, LLC and Knode Inc.

  • Revenue in GBP (TTM)15.36m
  • Net income in GBP-5.57m
  • Incorporated2015
  • Employees225.00
  • Location
    PureTech Health PLC501 Boylston St Ste 6102BOSTON 02116-3769United StatesUSA
  • Phone+1 (617) 482-2333
  • Fax+1 (617) 482-3337
  • Websitehttp://puretechhealth.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PRTC:LSE since
announced
Transaction
value
Ariya Therapeutics IncDeal completed02 Oct 201902 Oct 2019Deal completed14.12%666.98m
Data delayed at least 20 minutes, as of Jan 27 2020 16:35 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Recipharm AB (publ)574.27m16.99m604.44m5.36k48.941.698.271.052.952.95100.5185.620.56012.916.131,061,015.001.651.431.851.6849.4247.962.952.561.603.660.451955.8719.5424.57193.4911.0536.15--
Advanced Medical Solutions Group plc103.69m20.57m612.44m654.0029.963.3524.025.910.09510.09510.47940.85110.51462.784.92158,548.9010.2112.4310.9613.6360.4059.2819.8420.596.08106.250.049712.005.8711.5111.6914.6218.1617.08
Dottikon ES Holding AG133.54m23.46m641.44m595.0026.892.0715.864.8023.7223.72135.06307.500.36660.41665.14285,538.806.444.237.314.6582.7582.2417.5711.821.4192.050.000.00-6.6510.43-37.07--54.28--
AddLife AB252.76m10.85m655.90m927.0058.495.7824.792.595.135.13118.2751.891.215.286.783,637,572.005.25--9.98--34.76--4.32--0.455918.320.3956--6.36--7.48------
Biotest AG342.31m-8.03m689.65m1.79k--1.63--2.01-0.2664-0.339310.5912.430.37931.302.88243,896.60-0.86040.4722-0.96530.561929.9137.85-2.270.99872.48--0.455162.445.87-4.3821.31--4.94--
Pharma Mar SA77.35m-29.75m723.45m440.00------9.35-0.1593-0.16960.4142-0.02390.63780.74154.12153,011.70-24.55-4.94-45.24-7.9888.5176.90-38.48-5.600.6946-7.091.11--2.332.7742.59---18.18--
Bavarian Nordic A/S62.52m-45.44m738.24m461.00--3.44--11.81-12.56-12.5617.2858.610.19543.1513.891,321,115.00-14.20-0.5336-16.05-0.680140.3967.65-72.67-1.267.08-69.570.196---63.46-16.22-299.58--6.40--
Pharming Group N.V.135.21m31.51m755.36m183.0026.229.9020.515.590.05430.05430.23150.14370.77481.386.34875,453.6018.06-15.9731.49-24.7885.8883.4623.30-31.000.99831.800.4009--50.7881.59132.78--160.02--
Karo Pharma AB136.52m4.74m781.66m90.00123.902.6326.045.730.35220.352210.0016.620.1903----19,057,890.000.66046.250.86918.1754.68--3.4723.17--1.660.50437.15145.60102.854,428.63--12.43--
DBV Technologies SA12.08m-146.69m820.00m322.00--6.42--67.87-5.80-5.800.47163.220.06550.96350.597645,447.62-79.56-47.65-97.59-53.2992.9989.91-1,214.11-1,069.772.96-96.310.1722--22.0730.60-12.45--32.32--
Mithra Pharmaceuticals SA59.69m-72.04m837.57m129.00--14.95--14.03-2.28-1.821.861.700.21240.44545.14548,224.80-25.64-13.81-28.45-16.7593.4565.30-120.70-74.962.700.63220.8078--80.6326.7728.03--77.50--
Eckert & Ziegler AG150.31m18.47m860.36m812.0045.157.2930.525.724.274.2734.7826.430.7493.136.87226,019.009.465.7111.017.2048.2046.4912.648.062.9746.370.118733.9021.707.5739.0512.29-8.7014.87
Puretech Health PLC15.36m-5.57m864.67m225.00--3.21--56.28-0.0224-0.02240.05330.94480.0383--4.3268,280.97-13.04-28.57-17.99-45.76-----340.74-865.69----0.2374--718.4619.53-264.91--50.17--
BACHEM HOLDING AG241.86m39.96m908.87m1.12k44.235.5515.373.763.723.7222.4729.600.52151.045.52279,079.308.627.7911.249.6929.4832.1316.5216.240.896545.990.216181.217.9810.6011.6714.5928.539.46
Cosmo Pharmaceuticals NV42.68m-26.15m949.19m245.00--2.70--22.24-2.24-2.243.6429.600.0944.103.80176,559.90-5.7814.24-5.9515.2655.6769.02-61.5385.2221.00-3.430.2881---2.423.0944.50--30.55--
Zealand Pharma Aktieselskabet4.85m-57.40m1.01bn176.00--6.32--208.65-16.11-16.111.3639.360.0266--1,789.96288,315.40-31.41-0.8792-38.36-0.9888-----1,183.09-4.05----0.0464---72.1442.02311.18---2.44--
Data as of Jan 27 2020. Currency figures normalised to PureTech Health PLC's reporting currency: UK Pound GBX

Institutional shareholders

64.22%Per cent of shares held by top holders
HolderShares% Held
Invesco Asset Management Ltd.as of 31 Dec 201890.11m31.58%
Lansdowne Partners (UK) LLPas of 31 Dec 201827.40m9.60%
Baillie Gifford & Co.as of 31 Dec 201825.42m8.91%
Jupiter Asset Management Ltd.as of 31 Dec 201818.36m6.43%
M&G Investment Management Ltd.as of 01 Nov 20195.28m1.85%
Hargreave Hale Ltd.as of 01 Nov 20195.16m1.81%
DNCA Finance SAas of 30 Jun 20193.50m1.23%
Ruffer LLPas of 01 Nov 20193.00m1.05%
Bessemer Investment Management LLCas of 31 Jul 20192.71m0.95%
Majedie Asset Management Ltd.as of 30 Nov 20192.31m0.81%
More ▼
Data from 30 Aug 2019 - 30 Sep 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.